box seq

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: SCHENERMAN, Mark et al.	Art Unit: 1645
Serial No.: 10/751,744	Examiner: Robert A. Zeman
Filed: January 5, 2004	Atty. Docket: AE300US1
For: STABILIZED GLYCOPROTEINS	Confirmation No.: 6583

Mail Stop MISSING PARTS
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUBMISSION OF SUBSTITUTE SEQUENCE LISTING
INCLUDING STATEMENT per 37 C.F.R. §1.825(c) and (e)

Dear Sir:

Pursuant to the Notice To Comply, mailed May 12, 2006, Applicant hereby provides (1) a copy of the Notice To Comply; (2) a Substitute Paper Copy of the Substitute Sequence Listing; (3) a Computer Readable Form of said Substitute Sequence Listing; (4) an amendment directing entry of the same into the specification. Applicant submits that the amendment is fully supported in the application as filed.

Pursuant to 37 C.F.R. §1.825(c) and (e), the undersigned also states that the Substitute Paper Copy and the Substitute Computer Readable Form are the same and the replacement compact disc includes no new matter.

Respectfully submitted,

Date: May 31, 2006

Janet M. Martineau
Attorney for Applicants
Reg. No. 46,903

MEDIMMUNE, INC.
One MedImmune Way
Gaithersburg, Maryland 20878
(301) 398-4532 – Tel
(301) 398-9306 – Fax

PTO/SB/21 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission	72

Application Number	10/751,744
Filing Date	January 5, 2004
First Named Inventor	Mark SCHENERMAN
Art Unit	1645
Examiner Name	Robert A. Zeman
Attorney Docket Number	AE300US1

ENCLOSURES *(Check all that apply)*

- ☐ Fee Transmittal Form
  - ☐ Fee Attached
- ☑ Amendment/Reply
  - ☐ After Final
  - ☐ Affidavits/declaration(s)
- ☐ Extension of Time Request
- ☐ Express Abandonment Request
- ☐ Information Disclosure Statement
- ☐ Certified Copy of Priority Document(s)
- ☐ Reply to Missing Parts/ Incomplete Application
  - ☐ Reply to Missing Parts under 37 CFR 1.52 or 1.53
- ☐ Drawing(s)
- ☐ Licensing-related Papers
- ☐ Petition
- ☐ Petition to Convert to a Provisional Application
- ☐ Power of Attorney, Revocation Change of Correspondence Address
- ☐ Terminal Disclaimer
- ☐ Request for Refund
- ☐ CD, Number of CD(s) _____
  - ☐ Landscape Table on CD
- ☐ After Allowance Communication to TC
- ☐ Appeal Communication to Board of Appeals and Interferences
- ☐ Appeal Communication to TC **(Appeal Notice, Brief, Reply Brief)**
- ☐ Proprietary Information
- ☐ Status Letter
- ☑ Other Enclosure(s) (please Identify below):
  1. Submission of Substitute Sequence Listing (1pg); 2. Sequence Listing (67pgs); 3. (1) Seq. Listing Diskette; 4. copy of Notice to Comply (3pgs)

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	MEDIMMUNE, INC.		
Signature			
Printed name	Janet MARTINEAU		
Date	May 31, 2006	Reg. No.	46,903

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name		Date	

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/751,744	01/05/2004	Mark A. Schenerman	AE300US1	6583

36577 7590 05/12/2006

JOHNATHAN KLEIN-EVANS
ONE MEDIMMUNE WAY
GAITHERSBURG, MD 20878

JKE

EXAMINER	
ZEMAN, ROBERT A	

ART UNIT	PAPER NUMBER
1645	

DATE MAILED: 05/12/2006

AE300US1

Please find below and/or attached an Office communication concerning this application or proceeding.

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, DC 20231
www.uspto.gov

APPLICATION NO./CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR /PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
10/751,744			

EXAMINER	
Robert A. Zeman	
ART UNIT	PAPER
1645	

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R.. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to **Robert A. Zeman** whose telephone number is **(571) 272-0866.**

ROBERT ZEMAN
PATENT EXAMINER

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. . 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

[X] 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).

[ ] 2. This application does not contain, as a separate part of the disclosure on paper copy, a □Sequence Listing□ as required by 37 C.F.R. 1.821(c).

[ ] 3. A copy of the Sequence Listing in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).

[ ] 4. A copy of the Sequence Listing in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up Raw Sequence Listing.

[ ] 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).

[ ] 6. The paper copy of the Sequence Listing is not the same as the computer readable from of the □Sequence Listing□ as required by 37 C.F.R. 1.821(e).

[X] 7. Other: the specification contains sequences without the proper sequence identifiers (see page 81 for example.

Applicant Must Provide:

[X] An initial or substitute computer readable form (CRF) copy of the Sequence Listing..

[X] An initial or substitute paper copy of the Sequence Listing, as well as an amendment directing its entry into the specification.

[X] A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216
For CRF Submission Help, call (703) 308-4212
PatentIn Software Program Support
Technical Assistance.....703-287-0200
To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY